Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Yarrow Bioscience, Inc.
The registration statement filed by Yarrow Bioscience, Inc. was declared effective by the SEC on August 19, 2026. This effectiveness grants the company the legal authorization to issue and sell the securities detailed in the filing.…more
Yarrow Bioscience, Inc.
ADAR1 Capital Management, LLC and Daniel Schneeberger entered into a joint filing agreement on August 14, 2026, regarding the Schedule 13G filing for Yarrow Bioscience, Inc. common stock. This agreement formalizes the joint reporting of their share ownership in the company.…more
Yarrow Bioscience, Inc.
Yarrow Bioscience, Inc. has filed a SCHEDULE 13G/A, reflecting an update in the beneficial ownership status reported by Zhang Xiaofan. This filing serves as an official disclosure regarding changes in the investor's significant shareholding.…more
31 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
VYNE, Yarrow와 합병 및 50대 1 액면병합 진행
VYNE Therapeutics는 Yarrow Bioscience와의 합병을 앞두고 특별 현금 배당을 지급했으며, 7월 24일 50대 1 비율의 액면병합을 시행합니다. 합병 완료 후 사명은 Yarrow Bioscience로 변경되며 나스닥에서 새로운 티커로 거래될 예정입니다.…more